NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United t

Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transc

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that

Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 15 years by 4.89% on an annua

Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown

TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises

On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the c

Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impac

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an up

Royalty Pharma continues to deliver solid portfolio execution, supported by robust management and in

Royalty Pharma demonstrates high-quality, cash-generative compounding with durable royalty growth an

Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 27.34% on an annu

Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annu

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA

Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the compa

NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agr

Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase a

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raise

Royalty Pharma NASDAQ: RPRX raised its 2026 outlook for the second consecutive quarter after reporti

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in

Royalty Pharma (RPRX) came out with quarterly earnings of $1.32 per share, beating the Zacks Consens

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.32 per share which beat the analyst c

Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Net cash provided by

Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for s

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks E

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the ap

U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lo

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnin

Bank of New York Mellon Corp decreased its position in Royalty Pharma PLC (NASDAQ: RPRX) by 2.8% dur

Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royal

TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the pri

Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmen

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expandin

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raise

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.30 per share which beat the analyst c

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and

Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&D) co-funding agr

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with rep

Zymeworks Inc. (NASDAQ:ZYME) and Royalty Pharma plc (NASDAQ:RPRX) today announced an agreement for $

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.47 per share which beat the analyst c

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being

Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including re